O. Leiva
Hospital de Sant Pau
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by O. Leiva.
Transplantation Proceedings | 2009
Manuel Blanco; J. Medina; E. Gonzalez; M. Dominguez; Amor Rodríguez; M. Pamplona; Amado Andrés; O. Leiva; J.M. Morales
The aim of this study was to analyze the 30 third transplantations performed at our center since 1976. They were all from cadaveric donors. Recipient mean age was 40 years (range, 21-57 years). Twenty-one patients (70%) had hepatitis C virus infection and 16 (53%) were hypersensitized (panel-reactive antibodies [PRA] >50%), with a mean time on dialysis since second graft loss of 65 months (range, 1-250 months). The imaging tests showed iliac calcifications in 14 patients (47%). The graft was preferably placed in the iliac fossa (27/30). Twenty-five patients (83%) had prior graft nephrectomy and transplantectomy was performed at the same surgery in 2 cases. Immunosuppressive protocol was quadruple therapy in 23 patients (77%). At a mean follow-up of 43 months, 24 grafts were functioning. Mean serum creatinine was 1.5 mg/dL and Modification of Diet in Renal Disease (MDRD) clearance was 64.5 mL/min. Six grafts were lost: 3 due to acute rejection, 2 due to chronic allograft nephropathy, and 1 due to venous thrombosis. Four patients died: 2 due to infectious complications, 1 due to hepatic encephalopathy, and 1 to an accident with a functioning graft. The acute rejection rate was 30% and 4 patients had an acute humoral rejection episode. The main surgical complication was lymphocele in 7 cases (23%). Estimated survival at 5 years was 76% for grafts and 86% for patients. Graft survival worsened among patients with PRA > 80% and among those who had lost the previous grafts in the first month posttransplantation (P < .05). In conclusion, the outcomes of the third kidney transplantations encourage us to continue with this procedure. However, worse graft survival should be expected among hyperimmunized patients and among those who had lost previous grafts early in their course.
Transplantation Proceedings | 2009
J. Medina Polo; J.M. Morales; Manuel Blanco; J.F. Aguirre; Amado Andrés; Rafael Diaz; Carlos Jimenez; O. Leiva; J.C. Meneu; E. Moreno; M. Pamplona; J. Passas; Amor Rodríguez; F. de la Rosa
OBJECTIVE We evaluated the incidence of urological complications after simultaneous renal and pancreatic transplantation. PATIENTS AND METHODS We retrospectively reviewed urological complications following 107 simultaneous kidney-pancreas transplantations performed at our institution between March 1995 and June 2008. The 46 women and 61 men were of mean age 37.8 years (range, 25-66). The mean duration of diabetes mellitus was 23.0 years (range, 9-48) and the mean duration of dialysis was 19.9 months (range, 0-70). The exocrine pancreatic secretions were drained to bladder in 58 cases, or enterically in 49 patients. The mean length of follow-up was 51.7 months. RESULTS The most frequent urological complication was urinary tract infection, reported in 63.8% of patients: 42 bladder-drained and 25 enteric-drained (P = .011). Hematuria occurred in 13 patients (12.5%): 12 bladder-drained and 1 enteric-drained (P = .002). Five bladder-drained patients developed bladder calculi. Among 58 bladder-drained patients, reflux pancreatitis occurred in 28 patients and urine leaks related to the pancreatic graft occurred in 7 patients. Conversion of exocrine secretions from bladder to enteric diversion was required in 6 patients. One- and 3-year patient survival rates were 92.7% and 89.1%, respectively. Moreover, 1 and 3-year kidney graft survival rates were 90.6% and 84.4%, and pancreas graft survival rates were 78.1 and 70.3%, respectively. CONCLUSION Simultaneous kidney-pancreas transplantation with bladder drainage is associated with a high frequency of urological complications. Appropriate treatment can resolve most complications. In our opinion, both enteric and bladder drainage seemed to be safe and effective alternatives to manage pancreatic exocrine secretions.
The Journal of Urology | 2004
Josep Tabernero; Luis Paz-Ares; Ramon Salazar; Pilar Lianes M.D.; José Guerra; Joan Borràs; Humberto Villavicencio; O. Leiva; Hernán Cortés-Funes
Urology | 2006
A. Rodríguez Antolín; M. Blanco; F. De La Rosa; Felipe Villacampa; M. Pamplona; Amado Andrés; J.M. Morales; J.F. Aguirre; Rafael Diaz; Manuel Praga; O. Leiva
Archivos españoles de urología | 2013
Cabrera F; Felipe Villacampa; Duque G; O. Leiva
Archivos españoles de urología | 2013
Fernando Cabrera; Felipe Villacampa; Gemma Duque; O. Leiva
Urology | 2009
M.A. Cabeza; Alfredo Rodríguez Antolín; J. Romero; José Duarte; G. Duque; J. Medina-Polo; E. Lanzós; M. Domínguez; F. De La Rosa; M.J. García; Felipe Villacampa; O. Leiva
Urology | 2009
J. Medina Polo; J.M. Morales; J.F. Aguirre; Rafael Diaz; M. Pamplona; J. Passas; Amor Rodríguez; F. De La Rosa; Alejandro Manrique; O. Leiva
Urology | 2009
Daniel Castellano; F. De La Rosa; A. Rodríguez Antolín; Felipe Villacampa; Juan Manuel Sepúlveda; I. Ghanem; Angel Tejido; Amor Rodríguez; Hernán Cortés-Funes; O. Leiva
The Journal of Urology | 2009
Felipe Villacampa; Federico de la Rosa; M. Pamplona; Maria Blanco; Alfredo E. Rodriguez; J. Passas; Ana Hernández; Enrique Morales; Amado Andrés; Filogenes Aguirre; Rafael Diaz; O. Leiva
Collaboration
Dive into the O. Leiva's collaboration.
Commonwealth Scientific and Industrial Research Organisation
View shared research outputs